Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs HROW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 10–0 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: AVDL 4 – 2 HROW Matrix Metrics: AVDL 10 – 0 HROW

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Harrow, Inc. (HROW) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas HROW carries 32.2/100 (SELL) at $30.41 (62.9x Forward P/E, -2.0% operating margin).

  • Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile HROW is in a Breakdown options structure phase (RSI 52.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs HROW
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
HROW NASDAQ
Harrow, Inc. Common Stock
Pharmaceutical Preparations
$30.41
-5.35% 1D
Market Cap $1.2B
TTM Revenue $303M
Forward P/E 62.9x
Beta / 30D Vol 1.08β · 72% Vol
Unified Composite Score
32.2 / 100 SELL
Tech 20.0 Fund 43.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 52.6 · SMA20: $29.15 · SMA50: $30.14

6-Pillar Scorecard Institutional Category Breakdown (AVDL 4 – 2 HROW)

Columns: Metric · AVDL · HROW
1. Valuation Multiples AVDL
Forward P/E 28.8x 62.9x
Trailing P/E 16.8x 62.9x
PEG Ratio 0.07x N/M
EV / Revenue 8.5x 4.7x
2. Growth & Scale AVDL
Revenue Growth (YoY) +54.9% +38.6%
Earnings Growth (YoY) +0.0% +810.4%
TTM Revenue (USD) $249M $303M
Market Cap $2.1B $1.2B
3. Profitability & Quality AVDL
Gross Margin 94.9% 73.5%
Operating Margin 2.5% -2.0%
Net Profit Margin -0.1% -9.4%
Return on Equity (ROE) -0.3% -75.5%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) $2.7M EBITDA -$38M
Cash Flow Margin 1.1% EBITDA Mgn -12.7%
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $226M Net Debt (10.31x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HROW
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 2.4% (<1st %ile) 74.1% (8th %ile)
Put/Call OI Skew N/A 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat HROW
OpEx & R&D Intensity N/A 75.5% of Rev ($229M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (10) vs HROW (0)
Institutional Metric AVDL HROW Criterion Row Edge
Market Capitalization
Scale
$2.1B $1.2B Larger Scale AVDL
Trailing P/E Ratio
Valuation
16.8x 62.9x Lower Multiple AVDL
Forward P/E Ratio
Valuation
28.8x 62.9x Lower Multiple AVDL
Revenue Growth (YoY)
Growth
+54.9% +38.6% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% -2.0% Higher Margin AVDL
Net Profit Margin
Profitability
-0.1% -9.4% Higher Margin AVDL
Return on Equity (ROE)
Capital Efficiency
-0.3% -75.5% Higher ROE AVDL
52-Week Range Position
Momentum
89% ($6–$24) 16% ($26–$55) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 1.08β · 72% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 32.2 / 100 (SELL) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $303M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 73.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev N/M PEG · 4.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) -$38M ($226M Net Debt (10.31x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HROW +1.06 pp
AVDL: +0.65% · HROW: +1.71%
3M Horizon HROW +29.2 pp
AVDL: -6.32% · HROW: +22.88%
6M Horizon HROW +29.2 pp
AVDL: -6.32% · HROW: +22.88%
1Y Horizon HROW +29.2 pp
AVDL: -6.32% · HROW: +22.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs HROW. Trailing 12-month operating profitability (AVDL 2.5% vs HROW -2.0%) and valuation multiples (AVDL 28.8x vs HROW 62.9x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
HROW ADR TTM Benchmark FX-Normalized USD
TTM Revenue$303M
Gross Margin73.5%
Op. Margin-2.0%
ROE / Fwd P/E-75.5% · 62.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HROW BREAKDOWN
89d in phase · OBV ACCUMULATION
Current IV 74.1%
IV Percentile 8th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact HROW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $29.16 · IV 63.0%

HROW Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($2,916)

Compare $2,916 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 63.0% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Jan 15 '27 $25 / $23 Bull Put Spread

Sell 3x $25P · Buy 3x $23P · 59d

Net Entry $264 Credit
Max Credit / Yield +$264 (+78.6% RoM)
Max Risk / Buffer -17.3% Cushion ($336 Mgn)
5d Edge & Liquidity 73% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $30 / $26 Bear Put Spread

Buy 1x $30P · Sell 1x $26P · 31d

Net Entry $161 Debit
T+5d @ -5% Drop +$45 (+28%)
Max Risk / Buffer $161 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HROW Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.2B market capitalization and -2.0% operating margin.
OpEx & R&D Reinvestment 75.5% of Rev ($229M)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs HROW Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Harrow, Inc. (HROW) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas HROW carries 32.2/100 (SELL) at $30.41 (62.9x Forward P/E, -2.0% operating margin). Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile HROW is in a Breakdown options structure phase (RSI 52.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with HROW at +38.6% YoY revenue growth and +810.4% YoY earnings growth on $303M TTM revenue (73.5% gross margin, -2.0% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $303M for HROW. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 75.5% of Rev ($229M) (0 disclosures) for HROW.

AVDL screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas HROW trades at 62.9x Forward P/E, 62.9x Trailing P/E, N/M PEG, and 4.7x EV/Revenue (-12.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus HROW (-75.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, HROW carries 74.1% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.08β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.